US FDA Chief Scientist Hinton’s Departure Leaves Vacancy Atop Makena Decision Tree

 
• By Sue Sutter

Jacqueline O’Shaughnessy takes over as acting chief scientist following Denise Hinton’s move to the surgeon general’s office; Hinton previously had been tapped by acting commissioner Janet Woodcock to make a final decision on the accelerated approval status of Covis' preterm birth prevention drug Makena.  

Vacancy sign
FDA chief scientist Denise Hinton's departure means someone else will be responsible for deciding whether Covis' Makena stays on the market or goes. • Source: Alamy

More from US FDA

More from Agency Leadership